Skip to content
Toggle main navigation
EndoForum logo
EndoForum logo
  • Join Today
    Log in
    Select an available language
    EN

    Endocrine News

    Endocrine News provides an in-depth look at trends in the field of endocrinology as well as a closer look at recently published research.

    Filter by category
    All
    Adrenal
    Advocacy
    Bone and Mineral
    Cardiometabolic
    Clinical
    COVID-19
    Diabetes
    Diabetes News and Research
    Diabetes Research Articles
    Early Career Corner
    See all

    Results (20)

    X-Linked Hypophosphatemia: A “Family Diagnosis”

    X-Linked Hypophosphatemia: A “Family Diagnosis”

    X-linked hypophosphatemia can remain undiagnosed across generations when symptoms are mistaken for normal childhood development or ordinary family traits. Here, we look at diagnostic barriers, the importance of testing and genetic counseling, and how identifying one patient can prompt a cascade of family diagnoses. When Emily’s seven-month-old daughter Ila began pulling herself up to stand, […]The
    October 19, 2026
    Low ALP, Think HPP: Clinical Pearls in Hypophosphatasia

    Low ALP, Think HPP: Clinical Pearls in Hypophosphatasia

    On behalf of Endocrine Society’s Bone and Mineral Special Interest Group Steering Committee, Anika Anam, MD and Azarmindokht Khosravi, MD, discuss the diagnostic gap in hypophosphatasia (HPP) and preview the SIG’s upcoming October 29 webinar on hypophosphatasia ahead of World HPP Day on October 30, 2026. Persistently low alkaline phosphatase can be an overlooked indicator […]The post Low ALP, Thin
    October 15, 2026
    VIDEO: Semaglutide Linked to Lower Bone Fracture Risk

    VIDEO: Semaglutide Linked to Lower Bone Fracture Risk

    [VIDEO]: People taking semaglutide for diabetes had a lower rate of bone fractures compared to those taking other anti-obesity medications, according to research presented at ENDO 2026. Sun Kim, MD, MS, explains the significance of the findings. While these results highlight the potential bone-protective effects of semaglutide, the authors recommend that prospective studies be done […]The post VID
    September 2, 2026
    VIDEO: Menopausal Hormone Therapy Reduces Risk of Low Bone Mineral Density by 69%

    VIDEO: Menopausal Hormone Therapy Reduces Risk of Low Bone Mineral Density by 69%

    [VIDEO]: Women on menopausal hormone therapy face less risk of developing low bone mineral density, according to research presented at ENDO 2026. Diego Espinoza-Peralta, MD, MSc, describes the research findings.  Women who do not use menopausal hormone therapy have a greater risk of developing osteopenia and osteoporosis, which can lead to fractures, disability, and loss […]The post VIDEO: Menopau
    August 26, 2026
    July 2026 Dashboard

    July 2026 Dashboard

    Highlights from the world of endocrinology 15% The percentage by which fractures decreased when using semaglutide as compared to other weight-loss strategies. Semaglutide also appeared to help the most with weight loss in patients with diabetes. Source: ENDO 2026 presentation by Sun H. Kim, MD, MS, associate professor of medicine in the Division of Endocrinology, […]The post July 2026 Dashboard ap
    July 21, 2026
    Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient

    Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient

    A recent study from JCEM Case Reports reveals that denosumab, a human monoclonal antibody widely used to prevent fractures, can cause a rare “hungry bone syndrome-like state” even in purely bone-destroying (osteolytic) cancers such as multiple myeloma.The post Denosumab Triggers Paradoxical Hungry Bone Syndrome-Like State in Multiple Myeloma Patient appeared first on Endocrine News.
    July 6, 2026
    Boning Up: The Year in Bone ENDO 2026 Preview

    Boning Up: The Year in Bone ENDO 2026 Preview

    ENDO 2026 in Chicago will include a session titled “Year in Bone” featuring two leading experts in bone research who will review and discuss the most influential and cutting‑edge publications from the past year. Endocrine News provides a sneak peek of the talks on this “mysterious and dynamic tissue.”Last February, a paper appeared in the Journal of Bone and Mineral Research titled, “Romosozumab f
    May 27, 2026
    Breaking Point: Weight Loss Therapies and the Musculoskeletal Stakes

    Breaking Point: Weight Loss Therapies and the Musculoskeletal Stakes

    ENDO 2026 attendees who catch the session, “Weight Loss: Friend or Foe for Bone & Muscle?” will be in for a treat as three experts weigh in on the impact of various weight loss therapies on muscle and bone. Pharmacological, surgical, and even lifestyle impacts will be discussed and debated in this Sunday morning symposium.On Sunday, June 14, ENDO 2026 will feature “Weight Loss: Friend or Foe for B
    May 21, 2026
    ENDO 2026 Preview: Beyond Basic DXA

    ENDO 2026 Preview: Beyond Basic DXA

    At ENDO 2026, taking place June 13 – 16 in Chicago, “Beyond Basic DXA” is set to challenge how clinicians think about bone health assessment.Angela M. Cheung, MD, PhD, a professor of medicine at the University Health Network and the University of Toronto, will lead “Beyond Basic DXA” on Day 4 (Monday, June 15), a session designed for bone and mineral metabolism specialists ready to move past stand
    May 14, 2026
    Strategic Shifts: New Research Defines Best Ways to Switch Osteoporosis Meds

    Strategic Shifts: New Research Defines Best Ways to Switch Osteoporosis Meds

    Effective long-term management of osteoporosis requires a carefully choreographed sequence of medications, as certain drug transitions can significantly enhance or inadvertently undermine bone density, according to a clinical review published by researchers at Aarhus University.The article, “Approach to the Patient—Transitions in Osteoporosis Therapy,” appearing in The Journal of Clinical Endocrin
    May 12, 2026
    Beyond the Curve: How XLH Impacts Skeletal Maturation and Predicted Height

    Beyond the Curve: How XLH Impacts Skeletal Maturation and Predicted Height

    New clinical research has identified a significant delay in skeletal maturation among children with X-linked hypophosphatemia (XLH), with male patients experiencing notably more pronounced delays than females. The study, published in Journal of The Endocrine Society, highlights a significant gap between chronological age and bone age (BA). These findings provide clinicians with more precise benchm
    April 7, 2026
    PFAS Exposure May Weaken Teens’ Bones 

    PFAS Exposure May Weaken Teens’ Bones 

    Early-life exposure to per- and polyfluoroalkyl substances (PFAS) may influence how children’s bones develop during adolescence, according to new research published in the Journal of the Endocrine Society.PFAS are synthetic chemicals found in water, food and everyday products. These “forever chemicals,” many of which persist in the environment and in the human body, may interfere with normal devel
    March 17, 2026
    Research Redefines Bone Abnormality in Jansen’s Disease

    Research Redefines Bone Abnormality in Jansen’s Disease

    Scientists have uncovered a new, fundamental mechanism behind the severe skeletal abnormalities seen in Jansen metaphyseal chondrodysplasia (JMC), a rare genetic disorder characterized by short-limbed dwarfism. A new study reveals that the causative H223R-PTH1R gene mutation directly impairs mature bone cells, known as osteocytes, leading to bone structural irregularities and poor quality, a findi
    December 17, 2025
    Hidden Skeletal Consequences of Adolescent Obesity

    Hidden Skeletal Consequences of Adolescent Obesity

    New research reveals long-term bone health implicationsResearch presented at ENDO 2025 suggests that adolescents with both obesity and type 2 diabetes could be at a higher risk for fractures and osteoporosis later in life. Lead researcher Fida Bacha, MD, discusses her group’s findings as well as the impact of insulin resistance and hyperglycemia on bone development in this population.In new resear
    November 12, 2025
    The Hidden Hepatotoxicity of Zoledronic Acid

    The Hidden Hepatotoxicity of Zoledronic Acid

    The safety profile of zoledronic acid (ZOL), a powerful bisphosphonate widely used for osteoporosis and metastatic bone diseases in cancer patients, has historically been regarded as well-established. Common side effects such as fever, myalgia, and flu-like symptoms are manageable and transient. However, a recent case report in the JCEM Case Reports journal highlights a rare but serious concern: a
    November 6, 2025
    Following Up: Could a New Pharmacological Treatment Provide Hope for Hypoparathyroidism Patients?

    Following Up: Could a New Pharmacological Treatment Provide Hope for Hypoparathyroidism Patients?

    Approved a little more than a year ago by the U.S. Food and Drug Administration, palopegteriparatide was lauded by a panel of experts from around the world in a recently published consensus statement on hypoparathyroidism treatment. Aliya Khan, MD, talks to Endocrine News what this means for these patients’ treatment options, quality of life, and other pharmaceuticals on the horizon.In August 2022
    October 21, 2025
    String of Pearls: A Look at Rare Clinical Pearls from JCEM Case Reports

    String of Pearls: A Look at Rare Clinical Pearls from JCEM Case Reports

    The JCEM Case Reports Clinical Pearls session at ENDO 2025 featured three presentations of rare challenging endocrine cases that could answer questions for endocrinologists who could be treating patients with similar symptoms, possibly triggering further investigations that might lead to optimal outcomes. The audience for the third-annual JCEM Case Reports Clinical Pearls session at ENDO 2025 in S
    October 16, 2025
    Osteoporosis Treatment Rates Rise, But Millions Still Fall Through Cracks

    Osteoporosis Treatment Rates Rise, But Millions Still Fall Through Cracks

    A new study in The Journal of Clinical Endocrinology & Metabolism has revealed a concerning paradox in the management of osteoporosis in the United States. While the use of drug therapies for the bone-weakening disease has increased over the last decade, a significant and persistent trend of underdiagnosis means millions of high-risk patients are missing out on vital treatment, leaving them vulner
    October 8, 2025
    Closing the Gap: Highlighting FLS for Osteoporosis Management

    Closing the Gap: Highlighting FLS for Osteoporosis Management

    Divya Sistla, MD, FACP, a steering committee member of the Endocrine Society’s Early-Career Special Interest Group (SIG), discusses how the University of Pittsburgh Medical Center uses a multidisciplinary approach to successfully improve osteoporosis treatment via a fracture liaison service.In the United States, approximately 2 million new cases of osteoporotic fractures are diagnosed annually. Th
    October 6, 2025
    People Who Skip Breakfast and Eat Late Dinners May Have a Higher Risk of Osteoporosis 

    People Who Skip Breakfast and Eat Late Dinners May Have a Higher Risk of Osteoporosis 

    People who skip breakfast and eat late dinners may have an increased risk of developing osteoporosis, according to a new study published in the Journal of the Endocrine Society.Lifestyle habits, such as exercise, alcohol consumption and smoking, are known to increase people’s risk of osteoporosis, however little is known about the association between osteoporotic fracture and diet.“This study aime
    August 28, 2025
    Contact
    1 (888) 363-6762
    Cookies
    Reselect cookie settings
    Community engagement platform by Hivebrite.